DJIA51285.73 -237.33
S&P 5007376.86 23.13
NASDAQ24579.42 264.43
Russell 20002754.11 24.22
German DAX25820.36 -504.65
FTSE 10010673.94 -108.72
CAC 408139.00 -66.37
EuroStoxx 506161.55 -86.30
Nikkei 22557434.77 -3643.13
Hang Seng24481.86 -315.12
Shanghai Comp3649.18 -40.73
KOSPI5059.69 -324.11
Bloomberg Comm IDX134.79 -0.15
WTI Crude-fut117.70 0.00
Brent Crude-fut90.71 -0.10
Natural Gas3.46 0.03
Gasoline-fut2.77 0.00
Gold-fut4079.50 -15.50
Silver-fut51.97 0.37
Platinum-fut1537.00 22.50
Palladium-fut1021.50 -12.50
Copper-fut6.26 0.03
Aluminum-spot2995.00 0.00
Coffee-fut271.40 -6.00
Soybeans-fut1194.00 5.00
Wheat-fut590.00 -9.00
Bitcoin75792.54 -16.95
Ethereum USD2233.23 2.01
Litecoin52.58 1.08
Dogecoin0.07 0.00
EUR/USD1.1142 -0.0067
USD/JPY158.47 0.67
GBP/USD1.3351 -0.0091
USD/CHF0.8203 0.0034
USD IDX102.28 0.71
US 10-Yr TR4.856 0.019
GER 10-Yr TR3.2508 -0.0041
UK 10-Yr TR5.1559 -0.0013
JAP 10-Yr TR2.64 -0.009
Fed Funds4 0
SOFR3.92 -0.02
High-rise commercial buildings

Sub Markets

Topics

Alternative Assets  + Private Debt  | 
Aspen Neuroscience Receives $40M Credit Facility from Silicon Valley Bank

Aspen Neuroscience Receives $40M Credit Facility from Silicon Valley Bank

Aspen Neuroscience, a private biotech company developing the first autologous neuron replacement therapies to treat Parkinson’s disease, signed a $40 million credit facility with Silicon Valley Bank. Terms of the deal were not disclosed.

The San Diego-based company has recently announced the achievement of key pre-clinical and corporate milestones, including raising $147.5 million in Series B financing to support the planned studies of the company’s lead product candidate for Parkinson’s Disease, ANPD001: a first-in-kind iPSC based autologous cell therapy. The company also recently announced the start of its trial ready patient screening cohort study for ANPD001.

“This non-dilutive financing complements our Series B round from earlier in the year and provides significant financial flexibility on top of our already strong balance sheet,” said Kameel Farag, Chief Financial Officer of Aspen Neuroscience.

In October, Aspen announced that Kim Raineri joined the company as Chief Technology Officer and as a member of the company’s executive team.

Connect

Inside The Story

Aspen Neuroscience

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.